Possible nitric oxide modulation in protective effect of FK-506 against 3-nitropropionic acid-induced behavioral, oxidative, neurochemical, and mitochondrial alterations in rat brain

Drug and Chemical Toxicology

Volumn 33, Issue 4, 2010, Pages 377-392

  Kumar, Puneet ^a   Kalonia, Harikesh ^a   Kumar, Anil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

3 nitropropionic acid; Huntington's disease; Immunophilins; Mitochondria; Nitric oxide; Oxidative stress

Indexed keywords

3 NITROPROPIONIC ACID; ARGININE; CATALASE; DOPAMINE; MALONALDEHYDE; MITOCHONDRIAL ENZYME; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRITE; NORADRENALIN; SUPEROXIDE DISMUTASE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BODY WEIGHT; BRAIN CORTEX; BRAIN REGION; CELL ACTIVITY; CONTROLLED STUDY; CORPUS STRIATUM; GRIP STRENGTH; HIPPOCAMPUS; HUNTINGTON DISEASE LIKE SYNDROME; LOCOMOTION; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT;

ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; BRAIN; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; MALE; MITOCHONDRIA; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; NITRO COMPOUNDS; OXIDATIVE STRESS; PROPIONIC ACIDS; RATS; RATS, WISTAR; TACROLIMUS;

RATTUS; RODENTIA;

EID: 77956142985     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.3109/01480541003642050     Document Type: Article

References (64)

1. Alexi, T., Borlongan, C. V., Faull, R. L., Williams, C. E., Clark, R. G., Gluckman, P. D., et al. (2000). Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Neurobiology 60:409-413.
2. Andersen, J. K. (2004). Oxidative stress in neurodegeneration: cause or consequence. Nat Med 10:18-25.
3. Arii, T., Kamiya, T., Arii, K., Ueda, M., Nito, C., Katsura, K. I., et al. (2001). Neuroprotective efect of immunosuppressant FK-506 in transient focal ischemia in rat: Terapeutic time window for FK-506 in transient focal ischemia. Neurol Res 23:755-760.
4. Beckman, J. S. (1996). Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 9:836-844.
5. Benchoua, A., Trioulier, Y., Diguet, E., Malgorn, C., Gaillard, M.C., Dufour, N., et al. (2008). Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant Huntington's through the regulation of mitochondrial complex II. Hum Mol Genet 17:1446-1456.
6. Berman, S. B., Hastings, T. G. (1999). Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 73:1127-1137.
7. Beyer, C. E., Boikess, S., Luo, B., Dawson, L. A. (2002). Comparison of the efects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol 16:297-304.
8. Bezprozvanny, I., Hayden, M. R. (2004). Deranged neuronal calcium signaling and Huntington's disease. Biochem Biophys Res Commun 322:1310-1317.
9. Brouillet, E., Hantraye, P. (1995). Efects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Curr Opin Neuro 18:469-473.
10. Brown, G. C. (1999). Nitric oxide and mitochondrial respiration. Biochim Biophys Acta 1411:351-369.
11. Cowan, C. M., Fan, M. M., Fan, J., Shehadeh, J., Zhang, L. Y., Graham, R. K., et al. (2008). Polyglutamine-modulated stri-atal calpain activity in YAC transgenic Huntington disease mouse model: impact on NMDA receptor function and toxic-ity. J Neurosci. 28, 12725-12735.
12. Dawson, T. M., Steiner, J. P., Dawson, V. L., Dinerman, J. L., Uhl, G. R., Snyder, S. H. (1993). Immunosuppressant FK-506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA 90:9808-9812.
13. Deckel, A. W. (2001). Nitric oxide and nitric oxide synthase in Huntington's disease. J Neurosci Res 64:99-107.
14. Deckel, A. W., Volmer, P., Weiner, R., Gary, K. A., Covault, J., Sasso, D., et al. (2000). Dietary arginine alters time of symptom onset in Huntington's disease transgenic mice. Brain Res 875:187-195.
15. Deshpande, S. B., Hida, H., Takei, I. N., Masuda, T., Baba, H., Nishino, H. (2006). Involvement of nitric oxide in 3-nitropropionic acid-induced striatal toxicity in rats. Brain Res 1108:205-215.
16. Ghazinezami, B., Rahimpour, S., Gholipour, T., Ghasemi, M., Sadeghipour, H., Mehr, S. E. (2007). Pharmacologic preconditioning of random-pattern skin fap in rats using local cyclosporine and FK-506: interaction with nitric oxide system. Ann Plast Surg 59:435-440.
17. Gornall, A. G., Bardawill, C. J., David, M. M. (1949). Determination of serum proteins by means of the Biuret reaction. J Biol Chem 177:751-756.
18. 15N) nitrate in biological fuids. Ann Biochem 126:131-138.
19. Hersch, S. M., Rosas, H. D. (2008). Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics 5:226-236.
20. Houten, V. B., Woshner, V., Santos, J. H. (2006). Role of mitochon-drial DNA in toxic responses to oxidative stress. DNA Rep 5:145-152.
21. Joshi, D., Naidu, P. S., Singh, A., Kulkarni, S. K. (2005). Reversal of triazolam tolerance and withdrawal induced hyperlocomo-tor activity and anxiety by bupropion in mice. Pharmacology 75:93-97.
22. Kato, S., Nishio, H., Ogura, M., Takeuchi, K. (2007). Tacrolimus (FK-506), an immune suppressive agent, prevents indometh-acin-induced small intestinal ulceration in the rat: inhibition of inducible nitric oxide synthase expression. J Pharmacol Sci 103:40-47.
23. King, M. M., Huang, C. Y., Chock, B. P. (1984). Mammalian brain phosphoproteins as substrates for calcineurin. J Biol Chem 259:8080-8083.
24. King, T. E. (1967). Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Meth Enzymol 10:322-331.
25. King TE, Howard RL (1967) Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol 10, 275-284.
26. Klettner, A., Herdegen, T. (2003). FK-506 and its analogs\therapeutic potential for neurological disorders. Curr Drug Targ CNS Neurol Disord 2:153-162.
27. Kono, Y. (1978). Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay of superoxide dis-mutase. Arch Biochem Biophysics 186:189-195.
28. Kumar, P., Kalonia, H., Kumar, A. (2009). Sesamol attenuate 3-nitropropionic acid-induced Huntington-like behavioral, biochemical, and cellular alterations in rats. J Asian Nat Prod Res 11:439-450.
29. Kumar, P., Kumar, A. (2009a). Possible role of sertraline against 3-nitropropionic acid-induced behavioral, oxidative stress, and mitochondrial dysfunctions in rat brain. Prog Neuropsychopharmacol Biol Psychiatr 33:100-108.
30. Kumar, P., Kumar, A. (2009b). Possible neuroprotective efect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease. J Med Food 12:591-600.
31. Kumar, P., Kumar, A. (2009c). Neuroprotective efect of cyclosporine and FK506 against 3-nitropropionic acid-induced cognitive dysfunction and glutathione redox in rat: possible role of nitric oxide. Neurosci Res 63:302-314.
32. Kumar, P., Padi, S. S., Naidu, P. S., Kumar, A. (2006). Efect of res-veratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol 17(5-6):485-492.
33. Lee, W. T., Chang, C. (2004). Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease. Prog Neurobiol 72:87-110.
34. Liu, Y., Peterson, D. A., Kimura, H., Schubert, D. (1997). Mechanisms of cellular 3-(4,5-dimethylthiazol-2-yl)-2-,5-diphenyltetrazolinium bromide (MTT) reduction. J Neurochem 69:581-593.
35. Luck, H. (1971). Catalase. In: Bergmeyer, H. U. (Eds.), Methods of Enzymatic Analysis (pp 885-893), New York: Academic Press.
36. Ludolph, A. C., He, F., Spencer, P. S., Hammerstad, J., Sabri, M. (1991). 3-nitropropionic acid-exogenous animal neuro-toxin and possible human striatal toxin. Can J Neurol Sci 18:492-498.
37. Manáková, S., Singh, A., Kääriäinen, T., Taari, H., Kulkarni, S. K., Männistö, P. T. (2005). Failure of FK-506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective efects in SH-SY5Y dopaminergic cell. Brain Res 1038:83-91.
38. Massioui, N., Ouary, S., Chéruel, F., Hantraye, P., Brouillet, E. (2001). Perseverative behavior underlying attentional set-shifting defcits in rats chronically treated with the neuro-toxin, 3-nitropropionic acid. Exp Neurol 172:172-181.
39. Mogi, M., Togari, A., Tanaka, K., Ogawa, N., Ichinose, H., Nagatsu, T. (2000). Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine- lesioned striatum in rats is suppressed by immunosuppressant FK-506. Neurosci Lett 289:165-178.
40. +-linked state 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitro-propionic acid-induced rat model of Huntington's disease. J Neurochem 104:420-434.
41. Pardo, R. L., Colin, E., Régulier E. T., Aebischer P., Déglon N., Humbert S. (2006). Inhibition of calcineurin by FK-506 protects against polyglutamine-Huntington's toxicity through an increase of Huntington's phosphorylation at S421. J Neuro 26:1635-1645.
42. Pérez-Severiano, F., Escalante, B., Vergara, P., Ríos, C., Segovia, J. (2002). Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice trans-genic for the Huntington's disease mutation. Brain Res 951:36-42.
43. Picconi, B., Passino, E., Sgobio, C., Bonsi, P., Barone, I., Ghiglieri, V., et al. (2006). Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis 22:143-152.
44. Pong, K., Zaleska, M. M. (2003). Terapeutic implications for immunophilin ligands in the treatment of neurode-generative diseases. Curr Drug Targ CNS Neurol Disord 2:349-356.
45. Pubill, D., Verdaguer, E., Canudas, A. M., Sureda, F. X., Escubedo, E., Camarasa, J., et al. (2001). Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo. Br J Pharmacol 132:693-702.
46. Reeves, T. M., Phillips, L. L., Lee, N. N., Povlishock, J. T. (2007). Preferential neuroprotective efect of tacrolimus (FK-506) on unmyelinated axons following traumatic brain injury. Brain Res 1154:225-236.
47. Rodríguez-Martínez, E., Rugerio-Vargas, C., Rodríguez, A. I., Borgonio-Pérez, G., Rivas-Arancibia, S. (2004). Antioxidant efects of taurine, vitamin C, and vitamin E on oxidative damage in hippocampus caused by the administration of 3-nitro-propionic acid in rats. Int J Neurosci 114:1133-1145.
48. Sabatini, D. M., Lai, M. M., Snyder, S. H. (1997). Neural roles of immunophilins and their ligands. Mol Neurobiol 15:223-239.
49. Sasaki, T., Hamada, J., Shibata, M., Gotoh, J., Araki, N., Fukuuchi, Y. (2004). FK-506 abrogates delayed neuronal death via suppression of nitric oxide production in rats. Brain Res 1009:34-49.
50. Saydof, J. A., Liu, L. S., Garcia, R. A., Hu, Z., Li, D., von Borstel, R.W. (2003). Oral uridine pro-drug PN401 decreases neurodegen-eration, behavioral impairment, weight loss, and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease. Brain Res 994:44-54.
51. Sharkey, J., Butcher, S. P., Kelly, J. S. (1994). Endothelin-1 induced middle cerebral artery occlusion: pathological consequences and neuroprotective efects of MK801. J Auton Trans 49:177-185.
52. Sharkey, J., Crawford, J. H., Butcher, S. P., Marston, H. M. (1996). Tacrolimus (FK-506) ameliorates skilled motor defcits produced by middle cerebral artery occlusion in rats. Stroke 27:2282-2296.
53. Singh, A., Naidu, P. S., Kulkarni, S. K. (2003). Possible antioxidant and neuroprotective mechanisms of FK-506 in attenuating haloperidol-induced orofacial dyskinesia. Eur J Pharmacol 477:87-94.
54. Sottocasa, G. L., Kuylenstierna, B., Ernster, L., Bergstrand, A. (1967). An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J Cell Biol 32:415-428.
55. Steiner, J. P., Hamilton, G. S., Ross, D. T., Valentine, H. L., Guo, H., Connolly, M. A. (1997). Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegener-ative animal models. Proc Natl Acad Sci\USA 94:2019-2024.
56. Takamatsu, H., Tsukada, H., Noda, A., Kakiuchi, T., Nishiyama, S., Nishimura, S., et al. (2001). FK-506 attenuates early ischemic neuronal death in a monkey model of stroke. J Nucl Med 42:1833-11440
57. Teunissen, C. E., Markerink-van Ittersum, M., de Bruijn, C., Steinbusch, H. W., de Vente, J. (2002). Evaluation of 3-nitrotyrosine as a marker for 3-nitropropionic acid-induced oxidative stress in Lewis and Wistar rats and strain-specifc whole brain spheroid cultures. Brain Res 931:5-20.
58. Toung, T. J., Bhardwaj, A., Dawson, V. L., Dawson, T. M., Traystman, R. J., Hurn, P. D. (1999). Neuroprotective FK-506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats. Stroke 30:1279-1285.
59. Túnez, I., Feijóo, M., Collado, J. A., Medina, F. J., Peña, J., Muñoz Mdel, C., et al. (2007). Efect of testosterone on oxidative stress and cell damage induced by 3-nitropropionic acid in striatum of ovariectomized rats. Life Sci 80:1221-1227.
60. Tunez, I., Montilla, P., Munoz, M. D. C., Feijoo, M., Salcedo, M. (2004). Protective efect of nicotine on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. Eur J of Pharmacol 504:169-175.
61. Wills, E. D. (1966). Mechanism of lipid peroxide formation in animals. Biochem J 99:667-676.
62. Winter, C., Schenkel, J., Bürger, E., Eickmeier, C., Zimmermann, M., Herdegen, T. (2000). Te immunophilin ligand FK-506, but not GPI-1046, protects against neuronal death and inhibits c-Jun expression in the substantia nigra pars compacta following transection of the rat medial forebrain bundle. Neuroscience 95:753-776.
63. Wu, H. Y., Tomizawa, K., Oda, Y., Wei, F. Y., Lu, Y. F., Matsushita, M., et al. (2004). Critical role of calpain-mediated cleavage of calcineurin in excitotoxic neurodegeneration. J Biol Chem 279:4929-4940.
64. Yao, H., Zhou, J., Li, D., Wu, N., Bader, A., Höxtermann, S. (2005). FK-506 enhances triptolide-induced downregulation of cyclooxygenase-2, inducible nitric oxide synthase, as well as their products PGE2 and NO in TNF-alpha-stimulated syno-vial fbroblasts from rheumatoid arthritic patients. Eur J Med Res 10:110-116.